- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07718594
Modality-Specific Heart Rate Differences at Ventilatory Thresholds During Unified Ramp Testing
Evaluation of Heart Rate and Ventilatory Threshold Agreement Between Cycling and Running Under Strictly Standardized Ramp Conditions
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Participants Twenty-three healthy adults (12 men, 11 women; age 30.8 ± 5.6 years; BMI 21.8 ± 2.6 kg/m²) were recruited via institutional advertisements at a university hospital. Inclusion criteria were: age ≥ 20 years, familiarity with cycling and treadmill exercise, and a negative Physical Activity Readiness Questionnaire response. Exclusion criteria were: history of cardiovascular, pulmonary, or metabolic disease; musculoskeletal injuries limiting exercise range of motion; or medications affecting heart rate or ventilation. Participants fasted for 3 hours, abstained from vigorous exercise, alcohol, and caffeine for 24 hours prior to testing, and provided written informed consent. Data collection was conducted between February 2024 and November 2024. The protocol was approved by the Institutional Review Board of National Taiwan University Hospital (IRB Registration: 202311036RIND).
Experimental Design A randomized crossover design was employed. Participants completed two symptom-limited CPET sessions on a cycle ergometer (VIAsprint, Ergoline, Germany) and motorized treadmill (Ergosprint, Ergoline, Germany), separated by 7-14 days and conducted at the same time of day (±2 hours) to control for circadian effects. The randomized order minimized potential order effects and ensured that fatigue from the first test did not systematically bias results.
Cardiopulmonary Exercise Testing Protocol Gas Exchange Measurement and Safety Monitoring Breath-by-breath gas exchange was measured using a metabolic cart (Vmax Encore, CareFusion, USA), calibrated before each test with standard gases and a 3-L calibration syringe. Heart rate was monitored continuously via 12-lead electrocardiography (Cardiosoft, GE Healthcare, USA), providing greater temporal resolution than telemetric methods. Blood pressure was measured at rest and every 2 minutes during exercise to monitor safety and detect cardiovascular abnormalities.
Unified Ramp Protocol The central innovation was implementing a unified ramp protocol on both modalities to eliminate kinetic confounding.
Cycle Ergometer: Following a 3-minute unloaded warm-up (0 W), continuous ramp increases began at 20 W·min-¹ (men) or 15 W·min-¹ (women), targeting an 8-12 minute test duration to optimize threshold identification within a physiologically relevant window.
Treadmill: Using the Porszász algorithm, simultaneous adjustments to speed and grade produced metabolically equivalent work rate increases (20 or 15 W·min-¹), matched to cycling. Warm-up consisted of 3 minutes at 3-4 km/h, 0% grade. The Porszász protocol mathematically calculates the non-linear combination of speed and grade increases needed to produce a linear rise in metabolic demand, ensuring identical oxygen uptake kinetic demands despite different biomechanical constraints.
Maximal Effort Verification Participants exercised to volitional exhaustion or until safety criteria were met. Maximal effort was confirmed by meeting ≥2 of the following criteria: respiratory exchange ratio (RER) ≥ 1.10; heart rate within 10 bpm of age-predicted maximum (220 - age); rating of perceived exertion (RPE) ≥ 17 on the Borg 6-20 scale; or VO₂ plateau (≤150 mL·min-¹ increase despite increasing workload).
Threshold Determination Breath-by-breath gas exchange data were binned into 5-second moving averages to attenuate noise while preserving dynamic resolution at the threshold transition point. VT1 and VT2 were identified independently by two blinded, experienced raters using consensus criteria (V-slope method, ventilatory equivalents, end-tidal gas tensions). Blinding was maintained by removing all identifiers before threshold determination. Disagreements (2 cases) were adjudicated by a third blinded expert. Inter-rater reliability was excellent (ICC = 0.94 for VT1; ICC = 0.96 for VT2). Variables were extracted as 30-second averages centered on the identified threshold time point to ensure stability.
Statistical Analysis Primary and Secondary Outcomes Primary outcome: heart rate difference at VT1 and VT2 between modalities. Secondary outcomes: absolute and relative VO₂, EqO₂, EqCO₂, and O₂ pulse.
Data Analysis Methods Data normality was assessed using the Shapiro-Wilk test. Paired t-tests compared variables between modalities, with two-tailed significance testing at α = 0.05. Intraclass correlation coefficients (ICC; two-way mixed-effects, absolute agreement) assessed measurement reliability. Measurement error was quantified using the coefficient of variation (CV = SD of differences/mean), which normalizes variability to enable comparison across variables with different scales.
Bland-Altman Regression Analysis for Proportional Bias Bland-Altman analysis with linear regression tested for fixed versus proportional bias-the core statistical innovation distinguishing this study. The difference between modalities (Cycling - Treadmill) was regressed against the mean of the two measurements. A non-significant regression slope (p > 0.05) indicated fixed bias, whereas a significant slope (p < 0.05) indicated proportional bias. This approach directly tests whether correction factors should be constant across participants or adjusted based on individual physiological capacity.
All statistical analyses were performed using SPSS Statistics Version 20 (IBM Corp., Armonk, NY) for ICC and t-tests, and GraphPad Prism Version 10 (GraphPad Software, San Diego, CA) for Bland-Altman plots.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Taipei City
-
Taipei, Taipei City, Taiwan, 10630
- Cathay General Hospitla
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Age ≥ 20 years.
- Familiarity with both cycling and treadmill exercise.
- Negative response on the Physical Activity Readiness Questionnaire (PAR-Q).
Exclusion Criteria:
- History of cardiovascular, pulmonary, or metabolic disease.
- Musculoskeletal injuries limiting exercise range of motion.
- Use of medications known to affect heart rate or ventilation.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Cycling-First Sequence
Participants in this arm are randomized to perform the continuous ramp cardiopulmonary exercise testing (CPET) on a cycle ergometer first.
After a washout period of 7 to 14 days, they cross over to perform the standardized treadmill ramp testing.
|
Following a 3-minute unloaded warm-up (0 W), continuous ramp increases began at 20 W/min for men or 15 W/min for women, targeting an 8-12 minute test duration to volitional exhaustion.
Standardized ramp testing utilizing the Porszász algorithm.
Simultaneous adjustments to speed and grade mathematically produce a linear rise in metabolic demand (matched to 20 or 15 W/min based on sex), ensuring identical oxygen uptake kinetic demands to the cycling protocol.
|
|
Experimental: Treadmill-First Sequence
Participants in this arm are randomized to perform the standardized treadmill ramp cardiopulmonary exercise testing (CPET) using the Porszász algorithm first.
After a washout period of 7 to 14 days, they cross over to perform the cycle ergometer ramp testing.
|
Following a 3-minute unloaded warm-up (0 W), continuous ramp increases began at 20 W/min for men or 15 W/min for women, targeting an 8-12 minute test duration to volitional exhaustion.
Standardized ramp testing utilizing the Porszász algorithm.
Simultaneous adjustments to speed and grade mathematically produce a linear rise in metabolic demand (matched to 20 or 15 W/min based on sex), ensuring identical oxygen uptake kinetic demands to the cycling protocol.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Modality-Specific Heart Rate Differences at Ventilatory Thresholds (VT1 and VT2)
Zeitfenster: Identified during each 8 to 12-minute cardiopulmonary exercise test session (Sessions separated by 7 to 14 days).
|
The absolute difference in heart rate (measured in beats per minute, bpm) recorded at the first ventilatory threshold (VT1) and second ventilatory threshold (VT2) between cycle ergometry and treadmill running.
|
Identified during each 8 to 12-minute cardiopulmonary exercise test session (Sessions separated by 7 to 14 days).
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Oxygen Consumption (VO2) at Thresholds and Peak
Zeitfenster: Extracted as 30-second averages centered on the threshold time points and peak during each exercise test session.
|
Absolute and relative oxygen consumption (mL/kg/min) at VT1, VT2, and peak exercise.
|
Extracted as 30-second averages centered on the threshold time points and peak during each exercise test session.
|
|
Ventilatory Equivalent for Carbon Dioxide (EqCO2)
Zeitfenster: immediately after exercise test
|
VE/VCO2 ratio at VT1 and VT2 to assess cross-modal reliability.
|
immediately after exercise test
|
|
Oxygen Pulse (O2 pulse)
Zeitfenster: immediately after exercise test
|
Calculated as VO2 divided by heart rate (mL/beat) at VT1 and VT2 to evaluate stroke volume and tissue extraction markers across modalities.
|
immediately after exercise test
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 202311036RIND
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
IPD-Sharing-Zugriffskriterien
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
- ANALYTIC_CODE
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Pulsschlag
-
Region SkaneAnmeldung auf EinladungHerzinsuffizienz New York Heart Association (NYHA) Klasse II | Herzinsuffizienz New York Heart Association (NYHA) Klasse IIISchweden
-
Medical University of BialystokMedical University of Lodz; Poznan University of Medical Sciences; Nicolaus Copernicus... und andere MitarbeiterBeendetHerzinsuffizienz, systolisch | Herzinsuffizienz mit reduzierter Ejektionsfraktion | Herzinsuffizienz New York Heart Association Klasse IV | Herzinsuffizienz New York Heart Association Klasse IIIPolen
-
V-Wave LtdJohnson & JohnsonNoch keine RekrutierungHerzinsuffizienz kongestiv | Herzinsuffizienz und reduzierte Ejektionsfraktion | Herzinsuffizienz New York Heart Association Klasse III | Heart Failure Chronic
-
University of WashingtonAmerican Heart AssociationAbgeschlossenHerzinsuffizienz, kongestive | Mitochondriale Veränderung | Herzinsuffizienz New York Heart Association Klasse IVVereinigte Staaten
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
China National Center for Cardiovascular DiseasesChinese Academy of Medical Sciences, Fuwai HospitalAktiv, nicht rekrutierendLungenentzündung | Sepsis | Infektion | Driveline Heart-assisted Device Related InfectionChina
-
Portuguese Association of Interventional CardiologyMedtronicRekrutierungSchwere symptomatische Aortenstenose (definiert als New York Heart Association (NYHA) Klasse ≥ II)Portugal
-
University Hospital, GasthuisbergUnbekanntTransient Left Ventricular Ballooning SyndromeBelgien
-
NYU Langone HealthRekrutierungTako-Tsubo-Kardiomyopathie | Takotsubo-Kardiomyopathie | Broken-Heart-SyndromVereinigte Staaten
-
Medical University of South CarolinaAmerican Heart AssociationAbgeschlossenSingle Ventricle Heart Disease nach Fontan-OperationVereinigte Staaten
Klinische Studien zur Cycle Ergometer CPET
-
University of California, San FranciscoNational Cancer Institute (NCI)AbgeschlossenLokalisierter Prostatakrebs | Aktive Überwachung für ProstatakrebsVereinigte Staaten
-
University of OklahomaAbgeschlossenChronisch obstruktive Lungenerkrankung | Obstruktive SchlafapnoeVereinigte Staaten
-
Şensu DinçerAbgeschlossen
-
Baylor Research InstituteAbgeschlossen
-
University Hospital, BordeauxNoch keine RekrutierungImmunthrombozytopenische PurpuraFrankreich
-
VieCuri Medical CentreAbgeschlossen
-
University Hospitals of North Midlands NHS TrustRekrutierungBildgebung | Chirurgische FitnessVereinigtes Königreich
-
Massachusetts General HospitalAbgeschlossenInsulinresistenz | Übergewicht und AdipositasVereinigte Staaten
-
VieCuri Medical CentreAbgeschlossenDarmkrebs | Chirurgie | Bösartige kolorektale NeubildungenNiederlande
-
Medical University of GrazAbgeschlossen